RIL
SPRY icon

Rothschild Investment LLC’s ARS Pharmaceuticals SPRY Stock Holding History

Rothschild Investment LLC’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$737 Sell
92
-7
-7% -$60 ﹤0.01% 3163
2026
Q1 		$795 Buy
99
+83
+519% +$795 ﹤0.01% 2962
2025
Q4 		$186 Sell
16
-19
-54% -$185 ﹤0.01% 3127
2025
Q3 		$352 Sell
35
-130
-79% -$1.87K ﹤0.01% 2908
2025
Q2 		$2.88K Buy
165
+60
+57% +$866 ﹤0.01% 1815
2025
Q1 		$1.32K Buy
105
+60
+133% +$722 ﹤0.01% 2174
2024
Q4 		$475 Sell
45
-30
-40% -$420 ﹤0.01% 2554
2024
Q3 		$1.09K Buy
75
+60
+400% +$714 ﹤0.01% 2112
2024
Q2 		$128 Buy
+15
New +$133 ﹤0.01% 2644

Other funds holding SPRY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
PCML
Pavaki Capital Management LLC Pueblo, Colorado $287M AUM
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return

Rothschild Investment LLC's SPRY Position: Q2 2026 in Review

Rothschild Investment LLC reduced its ARS Pharmaceuticals (SPRY) stake by 7.1% in Q2 2026, selling an estimated $60 and leaving 92 shares worth $737. The position accounts for ﹤0.01% of the portfolio, ranked #3163.

Rothschild Investment LLC first reported a position in SPRY in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.88K in Q2 2025. 68 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Rothschild Investment LLC held 92 shares of ARS Pharmaceuticals worth $737 as of Q2 2026.
  • Rothschild Investment LLC sold 7 ARS Pharmaceuticals shares in Q2 2026, an estimated $60.
  • ARS Pharmaceuticals made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #3163 holding.
  • Rothschild Investment LLC first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Rothschild Investment LLC's ARS Pharmaceuticals position peaked at $2.88K in Q2 2025.
  • 68 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.